Structure Therapeutics Inc. has announced the initiation of a Phase 1 clinical study for ACCG-2671, its lead oral small molecule amylin receptor agonist developed for the treatment of obesity. ACCG-2671 was designed to leverage the metabolic benefits of amylin biology in an oral, once-daily small molecule format, with the goal of improving scalability, combinability, and patient access. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity, utilizing single-ascending dose and multiple-ascending dose cohorts. Results from this study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603555-en) on December 17, 2025, and is solely responsible for the information contained therein.